Description
+ Include: 14 videos + 15 pdfs, size: 1.54 GB
+ Target Audience: oncologist
+ Sample video: contact me for sample video
+ Information:
- Start date: 24 Feb 2023
- End date: 25 Feb 2023
- Location: Singapore, Republic of Singapore
Learning objectives
- To foster, educate and mentor the next generation of Phase I/Early Drug Development Programmes in Oncology centres from both the established and emerging economies in the Asia-Pacific region.
- To understand the fundamentals of establishing and running a successful Phase I/Early Drug Development Programme: from an in-depth understanding of trial selection to patient coordination, to running a programme, to effectively engaging with sponsors and fellow PIs, to regional and international engagement, and regulatory processes.
- To bridge the gap between the key stakeholders in the drug development process in the Asia-Pacific region: investigators, sponsors (Pharma and Biotech), Contract Research Organization (CRO), regulatory bodies.
+ Topics:
ESMO-Advanced-Course-on-Early-Drug-Development-2023-Programme.pdf
Session 1 Current designs of Phase 1 clinical trials.mp4
Session 1 Current designs of Phase 1 clinical trials.pdf
Session 1 Importance of Phase I trials in drug development Historical perspective.mp4
Session 1 Importance of Phase I trials in drug development Historical perspective.pdf
Session 1 Limitation of current designs and future designs.mp4
Session 1 Limitation of current designs and future designs.pdf
Session 2 Immunotherapy, biomarkers, combinational approach.mp4
Session 2 Immunotherapy, biomarkers, combinational approach.pdf
Session 2 Other agents e.g. drug conjugates, hormonal agents, cell-based therapies,..mp4
Session 2 Other agents e.g. drug conjugates, hormonal agents, cell-based therapies,..pdf
Session 2 Targeted therapy, biomarkers, combinatorial approach.mp4
Session 2 Targeted therapy, biomarkers, combinatorial approach.pdf
Session 3 Assessing efficacy in novel Phase I trials.mp4
Session 3 Assessing efficacy in novel Phase I trials.pdf
Session 3 Ethnic differences in drug tolerance and response.mp4
Session 3 Ethnic differences in drug tolerance and response.pdf
Session 3 Patient selection Genomic matching to Phase I trials, NGS, ctDNA, existing programmes.mp4
Session 3 Patient selection Genomic matching to Phase I trials, NGS, ctDNA, existing programmes.pdf
Session 3 Safety and adverse events management.mp4
Session 3 Safety and adverse events management.pdf
Session 4 Challenges Facing Covid-19 and lessons learnt.mp4
Session 4 Challenges Facing Covid-19 and lessons learnt.pdf
Session 4 Industry’s perspective Challenges, how to assess a site, metrics.mp4
Session 4 Industry’s perspective Challenges, how to assess a site, metrics.pdf
Session 4 Principal investigator’s perspective Assessing protocol, logistics, budget, resource allocation.mp4
Session 4 Principal investigator’s perspective Assessing protocol, logistics, budget, resource allocation.pdf
Welcome and course overview.mp4
Welcome and course overview.pdf
Reviews
There are no reviews yet.